- Gliclazide
- Glimepiride
- Glipizide
Sulfonylureas differ in duration of action and in metabolism, which may make some preferable to others in individual patients.
Type 2 Diabetes mellitus.
Sulfonylureas act by increasing insulin secretion from pancreatic islet cells. In order for them to be effective, there must be some residual beta-cell insulin secretion.
Sulfonylureas are given orally. They are often used in combination with other anti-diabetic drugs.
Gliclazide modified-release 30mg is approximately the equivalent of 80mg standard release Gliclazide.
Anti-fungals such as fluconazole and some antibiotics can increase the exposure to sulfonylureas.
Combination therapy with other anti-diabetic drugs may increase the risk of hypoglycaemia.
Patient education should include explanations about hypoglycaemia and how to recognise / manage it.
Absorption may be postponed by eating and therefore sulfonylureas should be given before meals.
